Explore ›
Finding
Finding
decline
Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).
| Effect size | 56% vs 94% |
| Comparator | 1 cycle of bridging chemotherapy prior to CD19-specific CAR T cell infusion |
| Effect summary | decline; 56% vs 94% |
| Adverse events | grade ≥ 3 infection significantly higher |
Connected entities
Interventions
Outcomes
Source
PMC9361393
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia